Compare SRPT & EXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | EXG |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | 2000 | 2006 |
| Metric | SRPT | EXG |
|---|---|---|
| Price | $17.12 | $9.33 |
| Analyst Decision | Hold | |
| Analyst Count | 29 | 0 |
| Target Price | ★ $25.85 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 445.0K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.78 | ★ N/A |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $8.25 |
| 52 Week High | $43.92 | $9.78 |
| Indicator | SRPT | EXG |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 50.50 |
| Support Level | $16.09 | $9.14 |
| Resistance Level | $19.32 | $9.37 |
| Average True Range (ATR) | 1.14 | 0.12 |
| MACD | -0.48 | -0.03 |
| Stochastic Oscillator | 8.24 | 32.29 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.